Eric Clambey
Concepts (410)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Gammaherpesvirinae | 8 | 2021 | 45 | 2.050 |
Why?
| Herpesviridae Infections | 6 | 2021 | 142 | 1.510 |
Why?
| CD8-Positive T-Lymphocytes | 13 | 2021 | 855 | 1.430 |
Why?
| Gene Expression Regulation, Viral | 5 | 2021 | 90 | 1.240 |
Why?
| T-Lymphocytes, Regulatory | 7 | 2021 | 372 | 1.140 |
Why?
| B7-H1 Antigen | 5 | 2024 | 198 | 0.910 |
Why?
| Receptor, Adenosine A2B | 4 | 2013 | 43 | 0.820 |
Why?
| Immunologic Memory | 8 | 2020 | 349 | 0.780 |
Why?
| Head and Neck Neoplasms | 7 | 2022 | 544 | 0.760 |
Why?
| Virus Replication | 4 | 2021 | 453 | 0.740 |
Why?
| Histocompatibility Antigens Class II | 2 | 2020 | 363 | 0.740 |
Why?
| Mice | 44 | 2024 | 16973 | 0.730 |
Why?
| RNA, Untranslated | 3 | 2021 | 117 | 0.710 |
Why?
| Virus Latency | 6 | 2021 | 84 | 0.700 |
Why?
| Host-Pathogen Interactions | 3 | 2019 | 355 | 0.690 |
Why?
| Flow Cytometry | 5 | 2018 | 1158 | 0.680 |
Why?
| Lung Neoplasms | 7 | 2023 | 2342 | 0.670 |
Why?
| Gene Expression Regulation, Neoplastic | 4 | 2024 | 1327 | 0.650 |
Why?
| Animals | 56 | 2024 | 35334 | 0.640 |
Why?
| Virus Activation | 5 | 2021 | 88 | 0.640 |
Why?
| Extracellular Signal-Regulated MAP Kinases | 1 | 2020 | 169 | 0.630 |
Why?
| Immunomodulation | 2 | 2019 | 92 | 0.620 |
Why?
| Ischemia | 4 | 2015 | 405 | 0.620 |
Why?
| Mitogen-Activated Protein Kinases | 1 | 2020 | 311 | 0.590 |
Why?
| Epigenesis, Genetic | 2 | 2020 | 617 | 0.570 |
Why?
| Clone Cells | 3 | 2008 | 262 | 0.560 |
Why?
| Tumor Microenvironment | 9 | 2021 | 627 | 0.550 |
Why?
| Mice, Inbred C57BL | 24 | 2023 | 5468 | 0.550 |
Why?
| Interleukin-10 | 1 | 2019 | 298 | 0.540 |
Why?
| Ikaros Transcription Factor | 2 | 2013 | 23 | 0.500 |
Why?
| Kidney Diseases | 2 | 2020 | 382 | 0.500 |
Why?
| G(M1) Ganglioside | 1 | 2015 | 7 | 0.490 |
Why?
| Interleukin-2 Receptor alpha Subunit | 3 | 2021 | 82 | 0.490 |
Why?
| RNA, Viral | 1 | 2019 | 620 | 0.490 |
Why?
| Hypoxia | 2 | 2013 | 1081 | 0.490 |
Why?
| Drug Resistance, Neoplasm | 4 | 2024 | 751 | 0.480 |
Why?
| T-Lymphocytes | 4 | 2017 | 1935 | 0.480 |
Why?
| Receptors, Antigen, T-Cell, alpha-beta | 2 | 2014 | 336 | 0.480 |
Why?
| Diagnostic Imaging | 1 | 2018 | 326 | 0.470 |
Why?
| Killer Cells, Natural | 3 | 2021 | 426 | 0.450 |
Why?
| Mice, Transgenic | 10 | 2019 | 2135 | 0.450 |
Why?
| Antineoplastic Agents, Immunological | 4 | 2021 | 181 | 0.440 |
Why?
| Mice, Knockout | 11 | 2023 | 2887 | 0.440 |
Why?
| Polycystic Kidney, Autosomal Dominant | 3 | 2023 | 254 | 0.430 |
Why?
| Antibodies | 1 | 2015 | 398 | 0.420 |
Why?
| Image Processing, Computer-Assisted | 1 | 2018 | 739 | 0.420 |
Why?
| RNA, Messenger | 2 | 2019 | 2697 | 0.410 |
Why?
| Aging | 5 | 2018 | 1770 | 0.410 |
Why?
| Forkhead Transcription Factors | 2 | 2019 | 184 | 0.410 |
Why?
| Cisplatin | 2 | 2024 | 298 | 0.390 |
Why?
| Interleukin-12 | 1 | 2013 | 118 | 0.390 |
Why?
| Tumor Necrosis Factor-alpha | 2 | 2020 | 1203 | 0.390 |
Why?
| CD4-Positive T-Lymphocytes | 5 | 2020 | 1058 | 0.370 |
Why?
| Immunotherapy | 4 | 2021 | 596 | 0.370 |
Why?
| Kidney | 5 | 2023 | 1382 | 0.370 |
Why?
| Hypoxia-Inducible Factor 1, alpha Subunit | 2 | 2012 | 275 | 0.370 |
Why?
| Gene Expression Regulation | 4 | 2015 | 2544 | 0.360 |
Why?
| Neutrophils | 2 | 2017 | 1209 | 0.360 |
Why?
| Basic Helix-Loop-Helix Transcription Factors | 1 | 2013 | 235 | 0.360 |
Why?
| Endotoxins | 1 | 2012 | 220 | 0.350 |
Why?
| Radioimmunotherapy | 2 | 2021 | 16 | 0.350 |
Why?
| Radiation Tolerance | 3 | 2021 | 98 | 0.350 |
Why?
| Pneumonia | 3 | 2017 | 618 | 0.330 |
Why?
| Programmed Cell Death 1 Receptor | 4 | 2020 | 232 | 0.320 |
Why?
| Cyclins | 2 | 2021 | 88 | 0.300 |
Why?
| Open Reading Frames | 2 | 2018 | 114 | 0.300 |
Why?
| Mice, Inbred BALB C | 8 | 2021 | 1248 | 0.300 |
Why?
| STAT3 Transcription Factor | 2 | 2020 | 194 | 0.300 |
Why?
| Carcinoma, Non-Small-Cell Lung | 3 | 2023 | 1050 | 0.300 |
Why?
| Oxygen | 1 | 2013 | 914 | 0.290 |
Why?
| Interferon-gamma | 3 | 2020 | 773 | 0.280 |
Why?
| Signal Transduction | 6 | 2019 | 4916 | 0.280 |
Why?
| Acute Kidney Injury | 2 | 2012 | 789 | 0.280 |
Why?
| Intestinal Mucosa | 1 | 2012 | 593 | 0.270 |
Why?
| Immunophenotyping | 2 | 2019 | 310 | 0.270 |
Why?
| Cyclin-Dependent Kinase Inhibitor p18 | 2 | 2018 | 13 | 0.270 |
Why?
| Viral Proteins | 4 | 2021 | 327 | 0.260 |
Why?
| Inflammation | 4 | 2020 | 2741 | 0.260 |
Why?
| Papillomavirus Infections | 2 | 2022 | 297 | 0.250 |
Why?
| Nuclear Proteins | 2 | 2021 | 659 | 0.250 |
Why?
| Dendritic Cells | 2 | 2021 | 481 | 0.230 |
Why?
| Cell Line, Tumor | 9 | 2024 | 3181 | 0.230 |
Why?
| Disease Models, Animal | 7 | 2020 | 4073 | 0.220 |
Why?
| Antineoplastic Agents | 3 | 2024 | 2044 | 0.210 |
Why?
| Antigens, Viral | 2 | 2021 | 179 | 0.210 |
Why?
| Humans | 35 | 2024 | 129527 | 0.210 |
Why?
| Cell Proliferation | 6 | 2020 | 2367 | 0.210 |
Why?
| Spleen | 2 | 2002 | 508 | 0.200 |
Why?
| Immunity, Cellular | 2 | 2019 | 265 | 0.200 |
Why?
| Lymphocyte Depletion | 2 | 2021 | 134 | 0.200 |
Why?
| Stomach Neoplasms | 1 | 2024 | 97 | 0.200 |
Why?
| Myeloid-Derived Suppressor Cells | 2 | 2020 | 64 | 0.200 |
Why?
| Cell Separation | 2 | 2018 | 315 | 0.200 |
Why?
| Epstein-Barr Virus Infections | 1 | 2024 | 95 | 0.200 |
Why?
| Polycystic Kidney Diseases | 1 | 2023 | 68 | 0.200 |
Why?
| Peritoneal Cavity | 1 | 2002 | 31 | 0.200 |
Why?
| Acute Lung Injury | 2 | 2017 | 280 | 0.190 |
Why?
| Sequence Deletion | 1 | 2002 | 178 | 0.190 |
Why?
| Lymphocytic choriomeningitis virus | 2 | 2018 | 24 | 0.180 |
Why?
| Adaptive Immunity | 2 | 2023 | 161 | 0.180 |
Why?
| Tumor Cells, Cultured | 2 | 2020 | 931 | 0.180 |
Why?
| Tryptophan | 1 | 2023 | 177 | 0.180 |
Why?
| RNA Polymerase III | 1 | 2021 | 26 | 0.180 |
Why?
| Urinary Bladder Neoplasms | 1 | 2024 | 225 | 0.180 |
Why?
| Pulmonary Disease, Chronic Obstructive | 1 | 2009 | 998 | 0.180 |
Why?
| Immune Tolerance | 2 | 2020 | 356 | 0.170 |
Why?
| Gamma Rays | 1 | 2020 | 54 | 0.170 |
Why?
| Epithelial Cells | 3 | 2018 | 1061 | 0.170 |
Why?
| Oligonucleotides, Antisense | 1 | 2020 | 111 | 0.170 |
Why?
| Cells, Cultured | 5 | 2018 | 4087 | 0.170 |
Why?
| Aldehyde-Lyases | 1 | 2020 | 3 | 0.170 |
Why?
| Thymocytes | 1 | 2020 | 34 | 0.160 |
Why?
| Splenectomy | 1 | 2020 | 58 | 0.160 |
Why?
| Sphingosine | 1 | 2020 | 40 | 0.160 |
Why?
| Complement Factor H | 1 | 2020 | 73 | 0.160 |
Why?
| Ileitis | 1 | 2020 | 32 | 0.160 |
Why?
| Radiosurgery | 1 | 2022 | 321 | 0.160 |
Why?
| Lysophospholipids | 1 | 2020 | 72 | 0.160 |
Why?
| Discoidin Domain Receptor 2 | 1 | 2019 | 4 | 0.160 |
Why?
| Promoter Regions, Genetic | 2 | 2021 | 1211 | 0.150 |
Why?
| Lymphocytic Choriomeningitis | 1 | 2018 | 14 | 0.150 |
Why?
| Cell Line | 7 | 2018 | 2774 | 0.150 |
Why?
| Receptor, EphB4 | 1 | 2019 | 36 | 0.150 |
Why?
| Ephrin-B2 | 1 | 2019 | 50 | 0.150 |
Why?
| Lymph Nodes | 2 | 2018 | 471 | 0.150 |
Why?
| Dasatinib | 1 | 2019 | 54 | 0.150 |
Why?
| Hepatitis A Virus Cellular Receptor 2 | 1 | 2018 | 30 | 0.150 |
Why?
| Genes, Reporter | 1 | 2019 | 265 | 0.150 |
Why?
| Monkey Diseases | 1 | 2018 | 20 | 0.150 |
Why?
| Varicellovirus | 1 | 2018 | 17 | 0.150 |
Why?
| Neoplasms, Experimental | 1 | 2019 | 170 | 0.140 |
Why?
| Carcinoma, Hepatocellular | 1 | 2020 | 270 | 0.140 |
Why?
| Carcinoma, Pancreatic Ductal | 1 | 2020 | 269 | 0.140 |
Why?
| Trans-Activators | 1 | 2020 | 392 | 0.140 |
Why?
| Neoplasm Proteins | 1 | 2020 | 417 | 0.140 |
Why?
| Receptors, Complement | 1 | 2017 | 122 | 0.140 |
Why?
| Transplantation Tolerance | 1 | 2017 | 35 | 0.130 |
Why?
| Islets of Langerhans Transplantation | 1 | 2017 | 63 | 0.130 |
Why?
| Crohn Disease | 1 | 2020 | 217 | 0.130 |
Why?
| Green Fluorescent Proteins | 1 | 2018 | 390 | 0.130 |
Why?
| Lymphocytes, Tumor-Infiltrating | 1 | 2018 | 204 | 0.130 |
Why?
| T-Lymphocyte Subsets | 2 | 2009 | 412 | 0.130 |
Why?
| Chemokines, CXC | 1 | 2016 | 70 | 0.130 |
Why?
| Anti-Inflammatory Agents | 1 | 2020 | 481 | 0.130 |
Why?
| Down-Regulation | 2 | 2016 | 631 | 0.130 |
Why?
| Blood Substitutes | 1 | 1996 | 25 | 0.120 |
Why?
| Cytotoxicity, Immunologic | 4 | 2019 | 220 | 0.120 |
Why?
| Drug Delivery Systems | 1 | 2019 | 337 | 0.120 |
Why?
| Cytokines | 3 | 2020 | 2018 | 0.120 |
Why?
| Mice, 129 Strain | 2 | 2013 | 87 | 0.120 |
Why?
| Immune Evasion | 1 | 2016 | 54 | 0.120 |
Why?
| Antigen Presentation | 1 | 2017 | 207 | 0.120 |
Why?
| Carcinoma, Squamous Cell | 1 | 2021 | 628 | 0.120 |
Why?
| Papillomaviridae | 1 | 2016 | 112 | 0.120 |
Why?
| Precursor Cells, B-Lymphoid | 1 | 2015 | 39 | 0.120 |
Why?
| Fusion Proteins, bcr-abl | 1 | 2015 | 69 | 0.120 |
Why?
| Liver Neoplasms | 1 | 2020 | 635 | 0.120 |
Why?
| Rhadinovirus | 1 | 2015 | 20 | 0.120 |
Why?
| Aminopeptidases | 2 | 2024 | 17 | 0.110 |
Why?
| Biomarkers | 3 | 2024 | 3968 | 0.110 |
Why?
| Proto-Oncogene Proteins c-myc | 1 | 2015 | 128 | 0.110 |
Why?
| Complement Activation | 1 | 2017 | 385 | 0.110 |
Why?
| V(D)J Recombination | 1 | 2014 | 8 | 0.110 |
Why?
| Adenosine | 2 | 2013 | 225 | 0.110 |
Why?
| Antiviral Agents | 1 | 2020 | 719 | 0.110 |
Why?
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2015 | 952 | 0.110 |
Why?
| Gene Expression | 1 | 2019 | 1461 | 0.110 |
Why?
| Combined Modality Therapy | 3 | 2023 | 1201 | 0.110 |
Why?
| Perioperative Period | 1 | 2013 | 52 | 0.110 |
Why?
| Mice, Inbred NOD | 1 | 2015 | 587 | 0.110 |
Why?
| Hemoglobins | 1 | 1996 | 337 | 0.110 |
Why?
| Virulence Factors | 1 | 2015 | 157 | 0.110 |
Why?
| Computational Biology | 1 | 2018 | 591 | 0.100 |
Why?
| Cell Transformation, Neoplastic | 1 | 2015 | 318 | 0.100 |
Why?
| Xenograft Model Antitumor Assays | 3 | 2024 | 804 | 0.100 |
Why?
| Antigens | 2 | 2020 | 356 | 0.100 |
Why?
| Graft Rejection | 1 | 2017 | 598 | 0.100 |
Why?
| Lymphocytes, Null | 1 | 2012 | 3 | 0.100 |
Why?
| Gene Rearrangement, beta-Chain T-Cell Antigen Receptor | 1 | 2012 | 26 | 0.100 |
Why?
| Pneumonia, Viral | 1 | 2018 | 342 | 0.100 |
Why?
| Thymus Gland | 1 | 2014 | 309 | 0.100 |
Why?
| Nerve Growth Factors | 1 | 2013 | 75 | 0.100 |
Why?
| 5'-Nucleotidase | 1 | 2013 | 39 | 0.100 |
Why?
| Pancreatic Neoplasms | 1 | 2020 | 875 | 0.100 |
Why?
| Thymoma | 1 | 2012 | 33 | 0.100 |
Why?
| Aspirin | 1 | 1996 | 378 | 0.100 |
Why?
| Lung | 3 | 2017 | 3928 | 0.100 |
Why?
| Intraoperative Complications | 1 | 2013 | 129 | 0.100 |
Why?
| Reperfusion | 1 | 2012 | 38 | 0.100 |
Why?
| Jurkat Cells | 1 | 2012 | 134 | 0.100 |
Why?
| Adenosine-5'-(N-ethylcarboxamide) | 1 | 2012 | 11 | 0.100 |
Why?
| Equilibrative Nucleoside Transporter 1 | 1 | 2012 | 17 | 0.100 |
Why?
| Perioperative Care | 1 | 2013 | 165 | 0.090 |
Why?
| Intestinal Diseases | 1 | 2012 | 36 | 0.090 |
Why?
| Liver | 1 | 2020 | 1836 | 0.090 |
Why?
| Antigenic Variation | 1 | 2011 | 10 | 0.090 |
Why?
| Lymphocyte Activation | 4 | 2020 | 1109 | 0.090 |
Why?
| Moloney murine leukemia virus | 1 | 2011 | 13 | 0.090 |
Why?
| Hypoxia-Inducible Factor 1 | 1 | 2012 | 72 | 0.090 |
Why?
| Diabetes Mellitus, Experimental | 1 | 2013 | 182 | 0.090 |
Why?
| Hospital Mortality | 1 | 2016 | 851 | 0.090 |
Why?
| Cell Hypoxia | 1 | 2012 | 226 | 0.090 |
Why?
| Mice, Mutant Strains | 1 | 2012 | 298 | 0.090 |
Why?
| Vaccines, Subunit | 1 | 2011 | 48 | 0.090 |
Why?
| Real-Time Polymerase Chain Reaction | 1 | 2012 | 328 | 0.090 |
Why?
| Viral Envelope Proteins | 1 | 2011 | 81 | 0.090 |
Why?
| MicroRNAs | 1 | 2017 | 677 | 0.090 |
Why?
| Gene Expression Profiling | 2 | 2019 | 1684 | 0.090 |
Why?
| Tumor Suppressor Proteins | 1 | 2013 | 311 | 0.090 |
Why?
| Adenocarcinoma | 1 | 2017 | 889 | 0.090 |
Why?
| RNA Interference | 1 | 2012 | 450 | 0.090 |
Why?
| Nitric Oxide | 1 | 1996 | 897 | 0.090 |
Why?
| Algorithms | 1 | 2018 | 1614 | 0.080 |
Why?
| Blotting, Western | 1 | 2013 | 1199 | 0.080 |
Why?
| Cancer Vaccines | 1 | 2011 | 164 | 0.080 |
Why?
| Female | 13 | 2020 | 68650 | 0.080 |
Why?
| Practice Guidelines as Topic | 1 | 2018 | 1510 | 0.080 |
Why?
| Colitis | 1 | 2012 | 245 | 0.080 |
Why?
| Sepsis | 1 | 2016 | 576 | 0.080 |
Why?
| Transforming Growth Factor beta | 1 | 2012 | 462 | 0.080 |
Why?
| Regional Blood Flow | 1 | 2012 | 464 | 0.080 |
Why?
| Purines | 1 | 2011 | 171 | 0.080 |
Why?
| Endothelium, Vascular | 1 | 1996 | 895 | 0.080 |
Why?
| Diabetic Nephropathies | 1 | 2013 | 284 | 0.080 |
Why?
| Male | 11 | 2020 | 63586 | 0.080 |
Why?
| Cell Differentiation | 2 | 2016 | 1895 | 0.080 |
Why?
| Intestines | 1 | 2012 | 350 | 0.080 |
Why?
| Integrin alpha4 | 1 | 2008 | 7 | 0.080 |
Why?
| ErbB Receptors | 2 | 2023 | 605 | 0.070 |
Why?
| Interleukin-1 | 1 | 2012 | 954 | 0.070 |
Why?
| Up-Regulation | 1 | 2011 | 832 | 0.070 |
Why?
| Mice, Nude | 2 | 2020 | 677 | 0.070 |
Why?
| Models, Immunological | 1 | 2008 | 96 | 0.070 |
Why?
| Membrane Proteins | 2 | 2021 | 1118 | 0.070 |
Why?
| Respiratory Mucosa | 1 | 2011 | 310 | 0.070 |
Why?
| Gastric Mucosa | 1 | 2007 | 53 | 0.070 |
Why?
| Phenotype | 2 | 2021 | 3058 | 0.070 |
Why?
| Gene Knockdown Techniques | 2 | 2018 | 315 | 0.070 |
Why?
| Virulence | 2 | 2015 | 255 | 0.070 |
Why?
| Salmonella Infections | 1 | 2007 | 54 | 0.060 |
Why?
| Health | 1 | 2007 | 75 | 0.060 |
Why?
| Salmonella enterica | 1 | 2007 | 55 | 0.060 |
Why?
| Oligonucleotide Array Sequence Analysis | 1 | 2008 | 754 | 0.060 |
Why?
| Immunity | 1 | 2007 | 138 | 0.060 |
Why?
| Polymerase Chain Reaction | 2 | 2021 | 1031 | 0.060 |
Why?
| Genetic Predisposition to Disease | 1 | 2012 | 2271 | 0.050 |
Why?
| B-Lymphocytes | 1 | 2009 | 816 | 0.050 |
Why?
| B7-1 Antigen | 1 | 2023 | 55 | 0.050 |
Why?
| Organoids | 1 | 2024 | 104 | 0.050 |
Why?
| Herpesvirus 4, Human | 1 | 2024 | 157 | 0.050 |
Why?
| Obesity | 1 | 2016 | 2875 | 0.050 |
Why?
| Tryptophan Oxygenase | 1 | 2023 | 34 | 0.050 |
Why?
| Indoleamine-Pyrrole 2,3,-Dioxygenase | 1 | 2023 | 55 | 0.050 |
Why?
| Viral Plaque Assay | 1 | 2002 | 29 | 0.050 |
Why?
| Postoperative Complications | 1 | 2013 | 2475 | 0.050 |
Why?
| 3T3 Cells | 1 | 2002 | 159 | 0.050 |
Why?
| Aniline Compounds | 1 | 2023 | 97 | 0.050 |
Why?
| Cell Communication | 2 | 2017 | 298 | 0.050 |
Why?
| Kynurenine | 1 | 2023 | 113 | 0.050 |
Why?
| Macrophages | 2 | 2019 | 1486 | 0.050 |
Why?
| Smoking | 1 | 2009 | 1501 | 0.050 |
Why?
| Tumor Necrosis Factor Receptor Superfamily, Member 9 | 1 | 2021 | 26 | 0.040 |
Why?
| Luciferases | 1 | 2021 | 147 | 0.040 |
Why?
| Basic-Leucine Zipper Transcription Factors | 1 | 2021 | 41 | 0.040 |
Why?
| Bacterial Proteins | 1 | 2007 | 837 | 0.040 |
Why?
| Transcription, Genetic | 2 | 2020 | 1416 | 0.040 |
Why?
| Cetuximab | 1 | 2021 | 94 | 0.040 |
Why?
| Neoplasms | 2 | 2024 | 2450 | 0.040 |
Why?
| Major Histocompatibility Complex | 1 | 2021 | 229 | 0.040 |
Why?
| Receptors, CCR | 1 | 2020 | 8 | 0.040 |
Why?
| Neoadjuvant Therapy | 1 | 2022 | 378 | 0.040 |
Why?
| Immunocompetence | 1 | 2000 | 42 | 0.040 |
Why?
| Platelet Count | 1 | 2020 | 82 | 0.040 |
Why?
| Tumor Burden | 1 | 2021 | 287 | 0.040 |
Why?
| Mutation | 2 | 2023 | 3702 | 0.040 |
Why?
| Gene Targeting | 1 | 2000 | 81 | 0.040 |
Why?
| Radiotherapy, Image-Guided | 1 | 2019 | 34 | 0.040 |
Why?
| Basophils | 1 | 2020 | 73 | 0.040 |
Why?
| Lymphocyte Subsets | 1 | 2020 | 84 | 0.040 |
Why?
| Suppressor of Cytokine Signaling 1 Protein | 1 | 2019 | 12 | 0.040 |
Why?
| Interferons | 1 | 2021 | 189 | 0.040 |
Why?
| Chemokine CXCL9 | 1 | 2019 | 27 | 0.040 |
Why?
| Sequence Analysis, DNA | 1 | 2002 | 776 | 0.040 |
Why?
| Leukocyte Count | 1 | 2020 | 324 | 0.040 |
Why?
| Mice, SCID | 1 | 2000 | 350 | 0.040 |
Why?
| Homeodomain Proteins | 2 | 2013 | 493 | 0.040 |
Why?
| DNA Repair | 1 | 2020 | 210 | 0.040 |
Why?
| Transfection | 1 | 2021 | 916 | 0.040 |
Why?
| Transforming Growth Factor beta1 | 1 | 2019 | 158 | 0.040 |
Why?
| Postoperative Period | 1 | 2020 | 329 | 0.040 |
Why?
| Myeloid Cells | 1 | 2020 | 141 | 0.040 |
Why?
| HEK293 Cells | 1 | 2021 | 695 | 0.040 |
Why?
| Pancreaticoduodenectomy | 1 | 2020 | 158 | 0.040 |
Why?
| Heterografts | 1 | 2019 | 134 | 0.040 |
Why?
| Gene Silencing | 1 | 2019 | 189 | 0.040 |
Why?
| TRPP Cation Channels | 1 | 2018 | 79 | 0.040 |
Why?
| Lymphocytes | 1 | 2020 | 377 | 0.040 |
Why?
| Repressor Proteins | 1 | 2021 | 404 | 0.040 |
Why?
| Cell Cycle | 1 | 2020 | 583 | 0.040 |
Why?
| RNA Transport | 1 | 2017 | 23 | 0.040 |
Why?
| Antibodies, Blocking | 1 | 2017 | 33 | 0.030 |
Why?
| Chemoradiotherapy | 1 | 2019 | 208 | 0.030 |
Why?
| Radiotherapy | 1 | 2018 | 185 | 0.030 |
Why?
| Macaca mulatta | 1 | 2018 | 150 | 0.030 |
Why?
| Complement C3d | 1 | 2017 | 65 | 0.030 |
Why?
| Poly(ADP-ribose) Polymerases | 1 | 2017 | 94 | 0.030 |
Why?
| Monocytes | 1 | 2020 | 554 | 0.030 |
Why?
| Protein Kinase Inhibitors | 1 | 2023 | 885 | 0.030 |
Why?
| Arenaviridae Infections | 1 | 2016 | 8 | 0.030 |
Why?
| Analysis of Variance | 1 | 2019 | 1286 | 0.030 |
Why?
| Ovalbumin | 1 | 2017 | 177 | 0.030 |
Why?
| Survival Analysis | 1 | 2020 | 1270 | 0.030 |
Why?
| Cell Degranulation | 1 | 2016 | 42 | 0.030 |
Why?
| Complement C3 | 1 | 2017 | 208 | 0.030 |
Why?
| Aged, 80 and over | 2 | 2020 | 7052 | 0.030 |
Why?
| Lectins, C-Type | 1 | 2016 | 71 | 0.030 |
Why?
| Papillomavirus E7 Proteins | 1 | 2016 | 11 | 0.030 |
Why?
| Granzymes | 1 | 2016 | 47 | 0.030 |
Why?
| Calcimycin | 1 | 1996 | 49 | 0.030 |
Why?
| Immunoglobulin M | 1 | 2017 | 276 | 0.030 |
Why?
| Molecular Targeted Therapy | 1 | 2019 | 391 | 0.030 |
Why?
| NG-Nitroarginine Methyl Ester | 1 | 1996 | 47 | 0.030 |
Why?
| Renal Artery | 1 | 1996 | 34 | 0.030 |
Why?
| Cyclic GMP | 1 | 1996 | 90 | 0.030 |
Why?
| Oncogene Proteins, Fusion | 1 | 2017 | 200 | 0.030 |
Why?
| B-Cell Activating Factor | 1 | 2015 | 21 | 0.030 |
Why?
| Transplantation, Homologous | 1 | 2017 | 402 | 0.030 |
Why?
| Neutralization Tests | 1 | 2015 | 73 | 0.030 |
Why?
| Immunity, Innate | 1 | 2021 | 804 | 0.030 |
Why?
| Cyclin-Dependent Kinase Inhibitor p27 | 1 | 2015 | 74 | 0.030 |
Why?
| Chemokines | 1 | 2016 | 227 | 0.030 |
Why?
| Cell Survival | 1 | 2018 | 1084 | 0.030 |
Why?
| Acetylcholine | 1 | 1996 | 184 | 0.030 |
Why?
| Nitric Oxide Synthase | 1 | 1996 | 233 | 0.030 |
Why?
| Stem Cell Niche | 1 | 2015 | 53 | 0.030 |
Why?
| Cyclic AMP | 1 | 1996 | 237 | 0.030 |
Why?
| Immunoblotting | 1 | 2015 | 303 | 0.030 |
Why?
| Cellular Senescence | 1 | 2016 | 173 | 0.030 |
Why?
| Immunohistochemistry | 1 | 2019 | 1684 | 0.030 |
Why?
| Dogs | 1 | 1996 | 385 | 0.030 |
Why?
| Autoimmunity | 1 | 2020 | 863 | 0.030 |
Why?
| Integrin alpha Chains | 1 | 2014 | 23 | 0.030 |
Why?
| Femoral Artery | 1 | 1996 | 174 | 0.030 |
Why?
| California | 1 | 2016 | 393 | 0.030 |
Why?
| Interleukin-27 | 1 | 2014 | 13 | 0.030 |
Why?
| Toll-Like Receptor 3 | 1 | 2014 | 27 | 0.030 |
Why?
| Poly I-C | 1 | 2014 | 62 | 0.030 |
Why?
| Toll-Like Receptor 7 | 1 | 2014 | 38 | 0.030 |
Why?
| CD11b Antigen | 1 | 2014 | 60 | 0.030 |
Why?
| DNA Primers | 1 | 2015 | 507 | 0.030 |
Why?
| Receptors, Antigen, T-Cell | 1 | 2018 | 707 | 0.030 |
Why?
| Cell Movement | 1 | 2018 | 942 | 0.030 |
Why?
| Bone Marrow | 1 | 2015 | 272 | 0.030 |
Why?
| In Vitro Techniques | 1 | 1996 | 1091 | 0.030 |
Why?
| Netrin-1 | 1 | 2013 | 12 | 0.030 |
Why?
| Uterine Cervical Neoplasms | 1 | 2016 | 230 | 0.030 |
Why?
| Adult | 3 | 2023 | 35505 | 0.030 |
Why?
| Gene Deletion | 1 | 2015 | 379 | 0.030 |
Why?
| Imidazoles | 1 | 2014 | 235 | 0.030 |
Why?
| Nanoparticles | 1 | 2017 | 376 | 0.030 |
Why?
| Adenosine Deaminase | 1 | 2013 | 29 | 0.030 |
Why?
| Mi-2 Nucleosome Remodeling and Deacetylase Complex | 1 | 2012 | 26 | 0.030 |
Why?
| Vasodilation | 1 | 1996 | 476 | 0.020 |
Why?
| Biomarkers, Tumor | 1 | 2019 | 1159 | 0.020 |
Why?
| Enzyme Inhibitors | 1 | 1996 | 825 | 0.020 |
Why?
| Adoptive Transfer | 1 | 2013 | 218 | 0.020 |
Why?
| Prognosis | 1 | 2020 | 3772 | 0.020 |
Why?
| Nucleoside Transport Proteins | 1 | 2012 | 7 | 0.020 |
Why?
| No-Reflow Phenomenon | 1 | 2012 | 7 | 0.020 |
Why?
| Dipyridamole | 1 | 2012 | 28 | 0.020 |
Why?
| Receptors, Purinergic P1 | 1 | 2012 | 27 | 0.020 |
Why?
| Chromosomal Proteins, Non-Histone | 1 | 2012 | 116 | 0.020 |
Why?
| Albuminuria | 1 | 2013 | 183 | 0.020 |
Why?
| Chimerism | 1 | 2012 | 31 | 0.020 |
Why?
| Membrane Glycoproteins | 1 | 2014 | 477 | 0.020 |
Why?
| Antigens, CD | 1 | 2014 | 485 | 0.020 |
Why?
| Gastrointestinal Diseases | 1 | 2013 | 197 | 0.020 |
Why?
| Phosphodiesterase Inhibitors | 1 | 2012 | 89 | 0.020 |
Why?
| Apoptosis | 1 | 2020 | 2488 | 0.020 |
Why?
| Dose-Response Relationship, Drug | 1 | 1996 | 2013 | 0.020 |
Why?
| DNA Methylation | 1 | 2016 | 606 | 0.020 |
Why?
| Receptors, Purinergic | 1 | 2011 | 21 | 0.020 |
Why?
| Disease Progression | 1 | 2018 | 2628 | 0.020 |
Why?
| Antibodies, Monoclonal | 1 | 2017 | 1366 | 0.020 |
Why?
| Transcriptome | 1 | 2016 | 875 | 0.020 |
Why?
| Epitopes, T-Lymphocyte | 1 | 2011 | 186 | 0.020 |
Why?
| Chemotaxis | 1 | 2011 | 130 | 0.020 |
Why?
| Alleles | 1 | 2012 | 843 | 0.020 |
Why?
| Fibroblasts | 1 | 2015 | 943 | 0.020 |
Why?
| Recombinant Proteins | 1 | 2013 | 1311 | 0.020 |
Why?
| Inflammasomes | 1 | 2011 | 126 | 0.020 |
Why?
| Lipopolysaccharides | 1 | 2013 | 872 | 0.020 |
Why?
| Immunoglobulin Class Switching | 1 | 2009 | 19 | 0.020 |
Why?
| Phagocytosis | 1 | 2011 | 362 | 0.020 |
Why?
| Aged | 2 | 2020 | 22063 | 0.020 |
Why?
| Age Factors | 1 | 2016 | 3150 | 0.020 |
Why?
| Infection Control | 1 | 2009 | 143 | 0.020 |
Why?
| Inflammation Mediators | 1 | 2011 | 503 | 0.020 |
Why?
| Middle Aged | 2 | 2020 | 31087 | 0.020 |
Why?
| Epitopes | 1 | 2009 | 473 | 0.020 |
Why?
| Organ Specificity | 1 | 2007 | 296 | 0.020 |
Why?
| Myocardial Infarction | 1 | 2013 | 1018 | 0.020 |
Why?
| Critical Illness | 1 | 2012 | 758 | 0.020 |
Why?
| DNA-Binding Proteins | 1 | 2012 | 1438 | 0.010 |
Why?
| Stroke | 1 | 2013 | 1071 | 0.010 |
Why?
| Transcription Factors | 1 | 2012 | 1642 | 0.010 |
Why?
| Vaccines | 1 | 2009 | 400 | 0.010 |
Why?
| Retrospective Studies | 1 | 2020 | 14532 | 0.010 |
Why?
| Risk Factors | 1 | 2016 | 9779 | 0.010 |
Why?
| Vaccination | 1 | 2009 | 1348 | 0.010 |
Why?
|
|
Clambey's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|